Renal transplantation in 4 patients with methylmalonic aciduria: A cell therapy for metabolic disease

Patients with methylmalonic acidemia (MMA) may develop many complications despite medical treatment, in particular, severe central nervous system damage and chronic kidney disease (CKD). A kidney transplant may partially correct the metabolic dysfunctions. Liver, kidney and combined liver–kidney tra...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Molecular genetics and metabolism 2013-09, Vol.110 (1-2), p.106-110
Hauptverfasser: Brassier, A., Boyer, O., Valayannopoulos, V., Ottolenghi, C., Krug, P., Cosson, M.A., Touati, G., Arnoux, J.B., Barbier, V., Bahi-Buisson, N., Desguerre, I., Charbit, M., Benoist, J.F., Dupic, L., Aigrain, Y., Blanc, T., Salomon, R., Rabier, D., Guest, G., de Lonlay, P., Niaudet, P.
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 110
container_issue 1-2
container_start_page 106
container_title Molecular genetics and metabolism
container_volume 110
creator Brassier, A.
Boyer, O.
Valayannopoulos, V.
Ottolenghi, C.
Krug, P.
Cosson, M.A.
Touati, G.
Arnoux, J.B.
Barbier, V.
Bahi-Buisson, N.
Desguerre, I.
Charbit, M.
Benoist, J.F.
Dupic, L.
Aigrain, Y.
Blanc, T.
Salomon, R.
Rabier, D.
Guest, G.
de Lonlay, P.
Niaudet, P.
description Patients with methylmalonic acidemia (MMA) may develop many complications despite medical treatment, in particular, severe central nervous system damage and chronic kidney disease (CKD). A kidney transplant may partially correct the metabolic dysfunctions. Liver, kidney and combined liver–kidney transplantations have been advocated but no guidelines are available to identify the most suitable organ to transplant. Four patients with MMA (mut° phenotype) received a kidney graft because of repeated metabolic decompensations, with progression to CKD in 3 patients (end-stage kidney disease in two patients and CKD stage III in one patient with an estimated glomerular filtration rate [eGFR] of 40ml/min/1.73m2) but normal renal function in one (eGFR of 93ml/min/1.73m2) before transplantation. The medium age at transplantation was 7.9y (5–10.2) and the median follow-up was 2.8years (1.8–4.6). Renal transplantation improved the relevant metabolic parameters in 4/4 patients and renal function in the patients with CKD. Plasma and urinary MMA levels immediately decreased and remained normal or subnormal (mean values of plasma MMA before transplantation 1530μmol/L versus 240μmol/L after transplantation, and mean values of urine MMA before transplantation 4700mmol/mol creatinine versus 2300mmol/mol creatinine after transplantation). No further acute metabolic decompensation was observed and protein-intake was increased from 0.60 to 0.83g/Kg/day. One patient transplanted at age 9.7years developed a hepatoblastoma at age 11years with subsequent neurological complications and eventually died. The three other patients are alive. Two of them remained neurologically stable. The 3rd patient who displayed choreoathetosis transiently improved his neurological condition immediately after transplantation and then remained stable. Kidney transplantation represents an interesting alternative therapeutic option in methylmalonic aciduria, for renal complications but also as a “cellular therapy” that may significantly reduce metabolic decompensations and hospitalizations. However, further neurological impairment remains possible. •Chronic kidney disease is an important complication in methylmalonic aciduria (MMA).•Kidney transplantation is a therapeutic option to correct end stage kidney disease.•Kidney transplantation significantly improves metabolic condition.•However, this treatment doesn't prevent neurological complications.
doi_str_mv 10.1016/j.ymgme.2013.05.001
format Article
fullrecord <record><control><sourceid>proquest_hal_p</sourceid><recordid>TN_cdi_hal_primary_oai_HAL_hal_01782590v1</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S1096719213001492</els_id><sourcerecordid>1500789962</sourcerecordid><originalsourceid>FETCH-LOGICAL-c496t-93e0147f3ca9e6d7eb9622ed05f56f6aa6c311d31a6c82f27bdba3af246056363</originalsourceid><addsrcrecordid>eNqFkV1rFDEUhoNYbK3-AkFyqRc75iSTzI7gxVLUCguFUq_DmcwZN8t8mWRb9t-bcdte6lVewnM-koexdyAKEGA-7Yvj8GugQgpQhdCFEPCCXYCozaqSwrx8ylDLc_Y6xn0GQNflK3YuVaVByeqC0S2N2PMUcIxzj2PC5KeR-5GXfM6ZxhT5g087PlDaHfsB-2n0jqPz7SF4_Mw33FGfO-wo4Hzk3RQWFJupz1jrI2GkN-yswz7S28fzkv389vXu6nq1vfn-42qzXbmyNmlVKxJQVp1yWJNpK2pqIyW1QnfadAbROAXQKshhLTtZNW2DCjtZGqGNMuqSfTz13WFv5-AHDEc7obfXm61d7gRUa6lrcQ-Z_XBi5zD9PlBMdvBxeQqONB2iBS1Eta7zBv9HS7mWFZR6QdUJdWGKMVD3vAYIu2ize_tXm120WaFttpKr3j8OODQDtc81T54y8OUEUP69e0_BRpfdOGp9IJdsO_l_DvgDwB2pXQ</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1428271452</pqid></control><display><type>article</type><title>Renal transplantation in 4 patients with methylmalonic aciduria: A cell therapy for metabolic disease</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>Brassier, A. ; Boyer, O. ; Valayannopoulos, V. ; Ottolenghi, C. ; Krug, P. ; Cosson, M.A. ; Touati, G. ; Arnoux, J.B. ; Barbier, V. ; Bahi-Buisson, N. ; Desguerre, I. ; Charbit, M. ; Benoist, J.F. ; Dupic, L. ; Aigrain, Y. ; Blanc, T. ; Salomon, R. ; Rabier, D. ; Guest, G. ; de Lonlay, P. ; Niaudet, P.</creator><creatorcontrib>Brassier, A. ; Boyer, O. ; Valayannopoulos, V. ; Ottolenghi, C. ; Krug, P. ; Cosson, M.A. ; Touati, G. ; Arnoux, J.B. ; Barbier, V. ; Bahi-Buisson, N. ; Desguerre, I. ; Charbit, M. ; Benoist, J.F. ; Dupic, L. ; Aigrain, Y. ; Blanc, T. ; Salomon, R. ; Rabier, D. ; Guest, G. ; de Lonlay, P. ; Niaudet, P.</creatorcontrib><description>Patients with methylmalonic acidemia (MMA) may develop many complications despite medical treatment, in particular, severe central nervous system damage and chronic kidney disease (CKD). A kidney transplant may partially correct the metabolic dysfunctions. Liver, kidney and combined liver–kidney transplantations have been advocated but no guidelines are available to identify the most suitable organ to transplant. Four patients with MMA (mut° phenotype) received a kidney graft because of repeated metabolic decompensations, with progression to CKD in 3 patients (end-stage kidney disease in two patients and CKD stage III in one patient with an estimated glomerular filtration rate [eGFR] of 40ml/min/1.73m2) but normal renal function in one (eGFR of 93ml/min/1.73m2) before transplantation. The medium age at transplantation was 7.9y (5–10.2) and the median follow-up was 2.8years (1.8–4.6). Renal transplantation improved the relevant metabolic parameters in 4/4 patients and renal function in the patients with CKD. Plasma and urinary MMA levels immediately decreased and remained normal or subnormal (mean values of plasma MMA before transplantation 1530μmol/L versus 240μmol/L after transplantation, and mean values of urine MMA before transplantation 4700mmol/mol creatinine versus 2300mmol/mol creatinine after transplantation). No further acute metabolic decompensation was observed and protein-intake was increased from 0.60 to 0.83g/Kg/day. One patient transplanted at age 9.7years developed a hepatoblastoma at age 11years with subsequent neurological complications and eventually died. The three other patients are alive. Two of them remained neurologically stable. The 3rd patient who displayed choreoathetosis transiently improved his neurological condition immediately after transplantation and then remained stable. Kidney transplantation represents an interesting alternative therapeutic option in methylmalonic aciduria, for renal complications but also as a “cellular therapy” that may significantly reduce metabolic decompensations and hospitalizations. However, further neurological impairment remains possible. •Chronic kidney disease is an important complication in methylmalonic aciduria (MMA).•Kidney transplantation is a therapeutic option to correct end stage kidney disease.•Kidney transplantation significantly improves metabolic condition.•However, this treatment doesn't prevent neurological complications.</description><identifier>ISSN: 1096-7192</identifier><identifier>EISSN: 1096-7206</identifier><identifier>DOI: 10.1016/j.ymgme.2013.05.001</identifier><identifier>PMID: 23751327</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>Amino Acid Metabolism, Inborn Errors - blood ; Amino Acid Metabolism, Inborn Errors - genetics ; Amino Acid Metabolism, Inborn Errors - pathology ; Amino Acid Metabolism, Inborn Errors - therapy ; Amino Acid Metabolism, Inborn Errors - urine ; Cell- and Tissue-Based Therapy ; Child ; Chronic renal disease ; Disease Progression ; Female ; Glomerular Filtration Rate ; Gynecology and obstetrics ; Human health and pathology ; Humans ; Kidney Transplantation ; Life Sciences ; Liver Transplantation ; Male ; Metabolic Diseases - genetics ; Metabolic Diseases - therapy ; Methylmalonic Acid - blood ; Methylmalonic Acid - urine ; Methylmalonic acidemia ; Renal Insufficiency, Chronic - genetics ; Renal Insufficiency, Chronic - pathology ; Renal Insufficiency, Chronic - therapy ; Renal transplantation</subject><ispartof>Molecular genetics and metabolism, 2013-09, Vol.110 (1-2), p.106-110</ispartof><rights>2013</rights><rights>Copyright © 2013. Published by Elsevier Inc.</rights><rights>Distributed under a Creative Commons Attribution 4.0 International License</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c496t-93e0147f3ca9e6d7eb9622ed05f56f6aa6c311d31a6c82f27bdba3af246056363</citedby><cites>FETCH-LOGICAL-c496t-93e0147f3ca9e6d7eb9622ed05f56f6aa6c311d31a6c82f27bdba3af246056363</cites><orcidid>0000-0002-0734-344X ; 0000-0002-3957-1359</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S1096719213001492$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>230,314,776,780,881,3537,27901,27902,65306</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/23751327$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink><backlink>$$Uhttps://hal.science/hal-01782590$$DView record in HAL$$Hfree_for_read</backlink></links><search><creatorcontrib>Brassier, A.</creatorcontrib><creatorcontrib>Boyer, O.</creatorcontrib><creatorcontrib>Valayannopoulos, V.</creatorcontrib><creatorcontrib>Ottolenghi, C.</creatorcontrib><creatorcontrib>Krug, P.</creatorcontrib><creatorcontrib>Cosson, M.A.</creatorcontrib><creatorcontrib>Touati, G.</creatorcontrib><creatorcontrib>Arnoux, J.B.</creatorcontrib><creatorcontrib>Barbier, V.</creatorcontrib><creatorcontrib>Bahi-Buisson, N.</creatorcontrib><creatorcontrib>Desguerre, I.</creatorcontrib><creatorcontrib>Charbit, M.</creatorcontrib><creatorcontrib>Benoist, J.F.</creatorcontrib><creatorcontrib>Dupic, L.</creatorcontrib><creatorcontrib>Aigrain, Y.</creatorcontrib><creatorcontrib>Blanc, T.</creatorcontrib><creatorcontrib>Salomon, R.</creatorcontrib><creatorcontrib>Rabier, D.</creatorcontrib><creatorcontrib>Guest, G.</creatorcontrib><creatorcontrib>de Lonlay, P.</creatorcontrib><creatorcontrib>Niaudet, P.</creatorcontrib><title>Renal transplantation in 4 patients with methylmalonic aciduria: A cell therapy for metabolic disease</title><title>Molecular genetics and metabolism</title><addtitle>Mol Genet Metab</addtitle><description>Patients with methylmalonic acidemia (MMA) may develop many complications despite medical treatment, in particular, severe central nervous system damage and chronic kidney disease (CKD). A kidney transplant may partially correct the metabolic dysfunctions. Liver, kidney and combined liver–kidney transplantations have been advocated but no guidelines are available to identify the most suitable organ to transplant. Four patients with MMA (mut° phenotype) received a kidney graft because of repeated metabolic decompensations, with progression to CKD in 3 patients (end-stage kidney disease in two patients and CKD stage III in one patient with an estimated glomerular filtration rate [eGFR] of 40ml/min/1.73m2) but normal renal function in one (eGFR of 93ml/min/1.73m2) before transplantation. The medium age at transplantation was 7.9y (5–10.2) and the median follow-up was 2.8years (1.8–4.6). Renal transplantation improved the relevant metabolic parameters in 4/4 patients and renal function in the patients with CKD. Plasma and urinary MMA levels immediately decreased and remained normal or subnormal (mean values of plasma MMA before transplantation 1530μmol/L versus 240μmol/L after transplantation, and mean values of urine MMA before transplantation 4700mmol/mol creatinine versus 2300mmol/mol creatinine after transplantation). No further acute metabolic decompensation was observed and protein-intake was increased from 0.60 to 0.83g/Kg/day. One patient transplanted at age 9.7years developed a hepatoblastoma at age 11years with subsequent neurological complications and eventually died. The three other patients are alive. Two of them remained neurologically stable. The 3rd patient who displayed choreoathetosis transiently improved his neurological condition immediately after transplantation and then remained stable. Kidney transplantation represents an interesting alternative therapeutic option in methylmalonic aciduria, for renal complications but also as a “cellular therapy” that may significantly reduce metabolic decompensations and hospitalizations. However, further neurological impairment remains possible. •Chronic kidney disease is an important complication in methylmalonic aciduria (MMA).•Kidney transplantation is a therapeutic option to correct end stage kidney disease.•Kidney transplantation significantly improves metabolic condition.•However, this treatment doesn't prevent neurological complications.</description><subject>Amino Acid Metabolism, Inborn Errors - blood</subject><subject>Amino Acid Metabolism, Inborn Errors - genetics</subject><subject>Amino Acid Metabolism, Inborn Errors - pathology</subject><subject>Amino Acid Metabolism, Inborn Errors - therapy</subject><subject>Amino Acid Metabolism, Inborn Errors - urine</subject><subject>Cell- and Tissue-Based Therapy</subject><subject>Child</subject><subject>Chronic renal disease</subject><subject>Disease Progression</subject><subject>Female</subject><subject>Glomerular Filtration Rate</subject><subject>Gynecology and obstetrics</subject><subject>Human health and pathology</subject><subject>Humans</subject><subject>Kidney Transplantation</subject><subject>Life Sciences</subject><subject>Liver Transplantation</subject><subject>Male</subject><subject>Metabolic Diseases - genetics</subject><subject>Metabolic Diseases - therapy</subject><subject>Methylmalonic Acid - blood</subject><subject>Methylmalonic Acid - urine</subject><subject>Methylmalonic acidemia</subject><subject>Renal Insufficiency, Chronic - genetics</subject><subject>Renal Insufficiency, Chronic - pathology</subject><subject>Renal Insufficiency, Chronic - therapy</subject><subject>Renal transplantation</subject><issn>1096-7192</issn><issn>1096-7206</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2013</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkV1rFDEUhoNYbK3-AkFyqRc75iSTzI7gxVLUCguFUq_DmcwZN8t8mWRb9t-bcdte6lVewnM-koexdyAKEGA-7Yvj8GugQgpQhdCFEPCCXYCozaqSwrx8ylDLc_Y6xn0GQNflK3YuVaVByeqC0S2N2PMUcIxzj2PC5KeR-5GXfM6ZxhT5g087PlDaHfsB-2n0jqPz7SF4_Mw33FGfO-wo4Hzk3RQWFJupz1jrI2GkN-yswz7S28fzkv389vXu6nq1vfn-42qzXbmyNmlVKxJQVp1yWJNpK2pqIyW1QnfadAbROAXQKshhLTtZNW2DCjtZGqGNMuqSfTz13WFv5-AHDEc7obfXm61d7gRUa6lrcQ-Z_XBi5zD9PlBMdvBxeQqONB2iBS1Eta7zBv9HS7mWFZR6QdUJdWGKMVD3vAYIu2ize_tXm120WaFttpKr3j8OODQDtc81T54y8OUEUP69e0_BRpfdOGp9IJdsO_l_DvgDwB2pXQ</recordid><startdate>20130901</startdate><enddate>20130901</enddate><creator>Brassier, A.</creator><creator>Boyer, O.</creator><creator>Valayannopoulos, V.</creator><creator>Ottolenghi, C.</creator><creator>Krug, P.</creator><creator>Cosson, M.A.</creator><creator>Touati, G.</creator><creator>Arnoux, J.B.</creator><creator>Barbier, V.</creator><creator>Bahi-Buisson, N.</creator><creator>Desguerre, I.</creator><creator>Charbit, M.</creator><creator>Benoist, J.F.</creator><creator>Dupic, L.</creator><creator>Aigrain, Y.</creator><creator>Blanc, T.</creator><creator>Salomon, R.</creator><creator>Rabier, D.</creator><creator>Guest, G.</creator><creator>de Lonlay, P.</creator><creator>Niaudet, P.</creator><general>Elsevier Inc</general><general>Elsevier</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>8FD</scope><scope>FR3</scope><scope>P64</scope><scope>RC3</scope><scope>1XC</scope><orcidid>https://orcid.org/0000-0002-0734-344X</orcidid><orcidid>https://orcid.org/0000-0002-3957-1359</orcidid></search><sort><creationdate>20130901</creationdate><title>Renal transplantation in 4 patients with methylmalonic aciduria: A cell therapy for metabolic disease</title><author>Brassier, A. ; Boyer, O. ; Valayannopoulos, V. ; Ottolenghi, C. ; Krug, P. ; Cosson, M.A. ; Touati, G. ; Arnoux, J.B. ; Barbier, V. ; Bahi-Buisson, N. ; Desguerre, I. ; Charbit, M. ; Benoist, J.F. ; Dupic, L. ; Aigrain, Y. ; Blanc, T. ; Salomon, R. ; Rabier, D. ; Guest, G. ; de Lonlay, P. ; Niaudet, P.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c496t-93e0147f3ca9e6d7eb9622ed05f56f6aa6c311d31a6c82f27bdba3af246056363</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2013</creationdate><topic>Amino Acid Metabolism, Inborn Errors - blood</topic><topic>Amino Acid Metabolism, Inborn Errors - genetics</topic><topic>Amino Acid Metabolism, Inborn Errors - pathology</topic><topic>Amino Acid Metabolism, Inborn Errors - therapy</topic><topic>Amino Acid Metabolism, Inborn Errors - urine</topic><topic>Cell- and Tissue-Based Therapy</topic><topic>Child</topic><topic>Chronic renal disease</topic><topic>Disease Progression</topic><topic>Female</topic><topic>Glomerular Filtration Rate</topic><topic>Gynecology and obstetrics</topic><topic>Human health and pathology</topic><topic>Humans</topic><topic>Kidney Transplantation</topic><topic>Life Sciences</topic><topic>Liver Transplantation</topic><topic>Male</topic><topic>Metabolic Diseases - genetics</topic><topic>Metabolic Diseases - therapy</topic><topic>Methylmalonic Acid - blood</topic><topic>Methylmalonic Acid - urine</topic><topic>Methylmalonic acidemia</topic><topic>Renal Insufficiency, Chronic - genetics</topic><topic>Renal Insufficiency, Chronic - pathology</topic><topic>Renal Insufficiency, Chronic - therapy</topic><topic>Renal transplantation</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Brassier, A.</creatorcontrib><creatorcontrib>Boyer, O.</creatorcontrib><creatorcontrib>Valayannopoulos, V.</creatorcontrib><creatorcontrib>Ottolenghi, C.</creatorcontrib><creatorcontrib>Krug, P.</creatorcontrib><creatorcontrib>Cosson, M.A.</creatorcontrib><creatorcontrib>Touati, G.</creatorcontrib><creatorcontrib>Arnoux, J.B.</creatorcontrib><creatorcontrib>Barbier, V.</creatorcontrib><creatorcontrib>Bahi-Buisson, N.</creatorcontrib><creatorcontrib>Desguerre, I.</creatorcontrib><creatorcontrib>Charbit, M.</creatorcontrib><creatorcontrib>Benoist, J.F.</creatorcontrib><creatorcontrib>Dupic, L.</creatorcontrib><creatorcontrib>Aigrain, Y.</creatorcontrib><creatorcontrib>Blanc, T.</creatorcontrib><creatorcontrib>Salomon, R.</creatorcontrib><creatorcontrib>Rabier, D.</creatorcontrib><creatorcontrib>Guest, G.</creatorcontrib><creatorcontrib>de Lonlay, P.</creatorcontrib><creatorcontrib>Niaudet, P.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>Technology Research Database</collection><collection>Engineering Research Database</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Genetics Abstracts</collection><collection>Hyper Article en Ligne (HAL)</collection><jtitle>Molecular genetics and metabolism</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Brassier, A.</au><au>Boyer, O.</au><au>Valayannopoulos, V.</au><au>Ottolenghi, C.</au><au>Krug, P.</au><au>Cosson, M.A.</au><au>Touati, G.</au><au>Arnoux, J.B.</au><au>Barbier, V.</au><au>Bahi-Buisson, N.</au><au>Desguerre, I.</au><au>Charbit, M.</au><au>Benoist, J.F.</au><au>Dupic, L.</au><au>Aigrain, Y.</au><au>Blanc, T.</au><au>Salomon, R.</au><au>Rabier, D.</au><au>Guest, G.</au><au>de Lonlay, P.</au><au>Niaudet, P.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Renal transplantation in 4 patients with methylmalonic aciduria: A cell therapy for metabolic disease</atitle><jtitle>Molecular genetics and metabolism</jtitle><addtitle>Mol Genet Metab</addtitle><date>2013-09-01</date><risdate>2013</risdate><volume>110</volume><issue>1-2</issue><spage>106</spage><epage>110</epage><pages>106-110</pages><issn>1096-7192</issn><eissn>1096-7206</eissn><abstract>Patients with methylmalonic acidemia (MMA) may develop many complications despite medical treatment, in particular, severe central nervous system damage and chronic kidney disease (CKD). A kidney transplant may partially correct the metabolic dysfunctions. Liver, kidney and combined liver–kidney transplantations have been advocated but no guidelines are available to identify the most suitable organ to transplant. Four patients with MMA (mut° phenotype) received a kidney graft because of repeated metabolic decompensations, with progression to CKD in 3 patients (end-stage kidney disease in two patients and CKD stage III in one patient with an estimated glomerular filtration rate [eGFR] of 40ml/min/1.73m2) but normal renal function in one (eGFR of 93ml/min/1.73m2) before transplantation. The medium age at transplantation was 7.9y (5–10.2) and the median follow-up was 2.8years (1.8–4.6). Renal transplantation improved the relevant metabolic parameters in 4/4 patients and renal function in the patients with CKD. Plasma and urinary MMA levels immediately decreased and remained normal or subnormal (mean values of plasma MMA before transplantation 1530μmol/L versus 240μmol/L after transplantation, and mean values of urine MMA before transplantation 4700mmol/mol creatinine versus 2300mmol/mol creatinine after transplantation). No further acute metabolic decompensation was observed and protein-intake was increased from 0.60 to 0.83g/Kg/day. One patient transplanted at age 9.7years developed a hepatoblastoma at age 11years with subsequent neurological complications and eventually died. The three other patients are alive. Two of them remained neurologically stable. The 3rd patient who displayed choreoathetosis transiently improved his neurological condition immediately after transplantation and then remained stable. Kidney transplantation represents an interesting alternative therapeutic option in methylmalonic aciduria, for renal complications but also as a “cellular therapy” that may significantly reduce metabolic decompensations and hospitalizations. However, further neurological impairment remains possible. •Chronic kidney disease is an important complication in methylmalonic aciduria (MMA).•Kidney transplantation is a therapeutic option to correct end stage kidney disease.•Kidney transplantation significantly improves metabolic condition.•However, this treatment doesn't prevent neurological complications.</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>23751327</pmid><doi>10.1016/j.ymgme.2013.05.001</doi><tpages>5</tpages><orcidid>https://orcid.org/0000-0002-0734-344X</orcidid><orcidid>https://orcid.org/0000-0002-3957-1359</orcidid></addata></record>
fulltext fulltext
identifier ISSN: 1096-7192
ispartof Molecular genetics and metabolism, 2013-09, Vol.110 (1-2), p.106-110
issn 1096-7192
1096-7206
language eng
recordid cdi_hal_primary_oai_HAL_hal_01782590v1
source MEDLINE; Elsevier ScienceDirect Journals
subjects Amino Acid Metabolism, Inborn Errors - blood
Amino Acid Metabolism, Inborn Errors - genetics
Amino Acid Metabolism, Inborn Errors - pathology
Amino Acid Metabolism, Inborn Errors - therapy
Amino Acid Metabolism, Inborn Errors - urine
Cell- and Tissue-Based Therapy
Child
Chronic renal disease
Disease Progression
Female
Glomerular Filtration Rate
Gynecology and obstetrics
Human health and pathology
Humans
Kidney Transplantation
Life Sciences
Liver Transplantation
Male
Metabolic Diseases - genetics
Metabolic Diseases - therapy
Methylmalonic Acid - blood
Methylmalonic Acid - urine
Methylmalonic acidemia
Renal Insufficiency, Chronic - genetics
Renal Insufficiency, Chronic - pathology
Renal Insufficiency, Chronic - therapy
Renal transplantation
title Renal transplantation in 4 patients with methylmalonic aciduria: A cell therapy for metabolic disease
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-31T12%3A02%3A11IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_hal_p&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Renal%20transplantation%20in%204%20patients%20with%20methylmalonic%20aciduria:%20A%20cell%20therapy%20for%20metabolic%20disease&rft.jtitle=Molecular%20genetics%20and%20metabolism&rft.au=Brassier,%20A.&rft.date=2013-09-01&rft.volume=110&rft.issue=1-2&rft.spage=106&rft.epage=110&rft.pages=106-110&rft.issn=1096-7192&rft.eissn=1096-7206&rft_id=info:doi/10.1016/j.ymgme.2013.05.001&rft_dat=%3Cproquest_hal_p%3E1500789962%3C/proquest_hal_p%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1428271452&rft_id=info:pmid/23751327&rft_els_id=S1096719213001492&rfr_iscdi=true